Reviews Taxotere


No reviews yet.

Taxotere Drug Description
TAXOTERE
(docetaxel) Injection Concentrate, Intravenous Infusion

WARNING
The incidence of treatment-related mortality associated with TAXOTERE therapy
is increased in patients with abnormal liver function, in patients receiving
higher doses, and in patients with non-small cell lung carcinoma and a history
of prior treatment with platinum-based chemotherapy who receive TAXOTERE as
a single agent at a dose of 100 mg/m2 [see Warnings and Precautions].
TAXOTERE should generally not be given to patients with bilirubin > upper
limit of normal (ULN), or to patients with SGOT and/or SGPT > 1.5 x ULN
concomitant with alkaline phosphatase > 2.5 x ULN. Patients with elevations
of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase
are at increased risk for the development of grade 4 neutropenia, febrile
neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase
> 1.5 x ULN also had a higher rate of febrile neutropenia grade 4 but did
not have an increased incidence of toxic death. Bilirubin, SGOT or SGPT, and
alkaline phosphatase values should be obtained prior to each cycle of TAXOTERE
therapy and reviewed by the treating physician. TAXOTERE therapy should not
be given to patients with neutrophil counts of < 1500 cells/mm3.
In order to monitor the occurrence of neutropenia, which may be severe and
result in infection, frequent blood cell counts should be performed on all
patients receiving TAXOTERE. Severe hypersensitivity reactions characterized
by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely
fatal anaphylaxis, have been reported in patients who received the recommended
3-day dexamethasone premedication. Hypersensitivity reactions require immediate
discontinuation of the TAXOTERE infusion and administration of appropriate
therapy [see Warnings and Precautions].
TAXOTERE must not be given to patients who have a history of severe hypersensitivity
reactions to TAXOTERE or to other drugs formulated with polysorbate 80 [see
Contraindications].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of
a 3-day dexamethasone premedication regimen. It was characterized by one or
more of the following events: poorly tolerated peripheral edema, generalized
edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac
tamponade, or pronounced abdominal distention (due to ascites) [see Warnings
and Precautions].

DRUG DESCRIPTION



What are the possible side effects of docetaxel (Taxotere)?

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Taxotere »




Docetaxel is an antineoplastic agent belonging to the taxoid family. It is
prepared by semisynthesis beginning with a precursor extracted from the renewable
needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl
ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one
4-acetate 2-benzoate, trihydrate. Docetaxel has the following structural formula:







Docetaxel is a white to almost-white powder with an empirical formula of C43H53NO14•3H2O,
and a molecular weight of 861.9. It is highly lipophilic and practically insoluble
in water. TAXOTERE (docetaxel) Injection Concentrate is a clear yellow to brownish-yellow
viscous solution. TAXOTERE is sterile, non-pyrogenic, and is available in single-dose
vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous). Each
mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80.
TAXOTERE Injection Concentrate requires dilution prior to use. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.
Last reviewed on RxList: 10/18/2007




Taxotere Drug Description
TAXOTERE
(docetaxel) Injection Concentrate, Intravenous Infusion

WARNING
The incidence of treatment-related mortality associated with TAXOTERE therapy
is increased in patients with abnormal liver function, in patients receiving
higher doses, and in patients with non-small cell lung carcinoma and a history
of prior treatment with platinum-based chemotherapy who receive TAXOTERE as
a single agent at a dose of 100 mg/m2 [see Warnings and Precautions].
TAXOTERE should generally not be given to patients with bilirubin > upper
limit of normal (ULN), or to patients with SGOT and/or SGPT > 1.5 x ULN
concomitant with alkaline phosphatase > 2.5 x ULN. Patients with elevations
of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase
are at increased risk for the development of grade 4 neutropenia, febrile
neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase
> 1.5 x ULN also had a higher rate of febrile neutropenia grade 4 but did
not have an increased incidence of toxic death. Bilirubin, SGOT or SGPT, and
alkaline phosphatase values should be obtained prior to each cycle of TAXOTERE
therapy and reviewed by the treating physician. TAXOTERE therapy should not
be given to patients with neutrophil counts of < 1500 cells/mm3.
In order to monitor the occurrence of neutropenia, which may be severe and
result in infection, frequent blood cell counts should be performed on all
patients receiving TAXOTERE. Severe hypersensitivity reactions characterized
by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely
fatal anaphylaxis, have been reported in patients who received the recommended
3-day dexamethasone premedication. Hypersensitivity reactions require immediate
discontinuation of the TAXOTERE infusion and administration of appropriate
therapy [see Warnings and Precautions].
TAXOTERE must not be given to patients who have a history of severe hypersensitivity
reactions to TAXOTERE or to other drugs formulated with polysorbate 80 [see
Contraindications].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of
a 3-day dexamethasone premedication regimen. It was characterized by one or
more of the following events: poorly tolerated peripheral edema, generalized
edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac
tamponade, or pronounced abdominal distention (due to ascites) [see Warnings
and Precautions].

DRUG DESCRIPTION



What are the possible side effects of docetaxel (Taxotere)?

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Taxotere »




Docetaxel is an antineoplastic agent belonging to the taxoid family. It is
prepared by semisynthesis beginning with a precursor extracted from the renewable
needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl
ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one
4-acetate 2-benzoate, trihydrate. Docetaxel has the following structural formula:







Docetaxel is a white to almost-white powder with an empirical formula of C43H53NO14•3H2O,
and a molecular weight of 861.9. It is highly lipophilic and practically insoluble
in water. TAXOTERE (docetaxel) Injection Concentrate is a clear yellow to brownish-yellow
viscous solution. TAXOTERE is sterile, non-pyrogenic, and is available in single-dose
vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous). Each
mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80.
TAXOTERE Injection Concentrate requires dilution prior to use. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.
Last reviewed on RxList: 10/18/2007




Taxotere Drug Description
TAXOTERE
(docetaxel) Injection Concentrate, Intravenous Infusion

WARNING
The incidence of treatment-related mortality associated with TAXOTERE therapy
is increased in patients with abnormal liver function, in patients receiving
higher doses, and in patients with non-small cell lung carcinoma and a history
of prior treatment with platinum-based chemotherapy who receive TAXOTERE as
a single agent at a dose of 100 mg/m2 [see Warnings and Precautions].
TAXOTERE should generally not be given to patients with bilirubin > upper
limit of normal (ULN), or to patients with SGOT and/or SGPT > 1.5 x ULN
concomitant with alkaline phosphatase > 2.5 x ULN. Patients with elevations
of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase
are at increased risk for the development of grade 4 neutropenia, febrile
neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase
> 1.5 x ULN also had a higher rate of febrile neutropenia grade 4 but did
not have an increased incidence of toxic death. Bilirubin, SGOT or SGPT, and
alkaline phosphatase values should be obtained prior to each cycle of TAXOTERE
therapy and reviewed by the treating physician. TAXOTERE therapy should not
be given to patients with neutrophil counts of < 1500 cells/mm3.
In order to monitor the occurrence of neutropenia, which may be severe and
result in infection, frequent blood cell counts should be performed on all
patients receiving TAXOTERE. Severe hypersensitivity reactions characterized
by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely
fatal anaphylaxis, have been reported in patients who received the recommended
3-day dexamethasone premedication. Hypersensitivity reactions require immediate
discontinuation of the TAXOTERE infusion and administration of appropriate
therapy [see Warnings and Precautions].
TAXOTERE must not be given to patients who have a history of severe hypersensitivity
reactions to TAXOTERE or to other drugs formulated with polysorbate 80 [see
Contraindications].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of
a 3-day dexamethasone premedication regimen. It was characterized by one or
more of the following events: poorly tolerated peripheral edema, generalized
edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac
tamponade, or pronounced abdominal distention (due to ascites) [see Warnings
and Precautions].

DRUG DESCRIPTION



What are the possible side effects of docetaxel (Taxotere)?

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Taxotere »




Docetaxel is an antineoplastic agent belonging to the taxoid family. It is
prepared by semisynthesis beginning with a precursor extracted from the renewable
needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl
ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one
4-acetate 2-benzoate, trihydrate. Docetaxel has the following structural formula:







Docetaxel is a white to almost-white powder with an empirical formula of C43H53NO14•3H2O,
and a molecular weight of 861.9. It is highly lipophilic and practically insoluble
in water. TAXOTERE (docetaxel) Injection Concentrate is a clear yellow to brownish-yellow
viscous solution. TAXOTERE is sterile, non-pyrogenic, and is available in single-dose
vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous). Each
mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80.
TAXOTERE Injection Concentrate requires dilution prior to use. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.
Last reviewed on RxList: 10/18/2007




Taxotere Drug Description
TAXOTERE
(docetaxel) Injection Concentrate, Intravenous Infusion

WARNING
The incidence of treatment-related mortality associated with TAXOTERE therapy
is increased in patients with abnormal liver function, in patients receiving
higher doses, and in patients with non-small cell lung carcinoma and a history
of prior treatment with platinum-based chemotherapy who receive TAXOTERE as
a single agent at a dose of 100 mg/m2 [see Warnings and Precautions].
TAXOTERE should generally not be given to patients with bilirubin > upper
limit of normal (ULN), or to patients with SGOT and/or SGPT > 1.5 x ULN
concomitant with alkaline phosphatase > 2.5 x ULN. Patients with elevations
of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase
are at increased risk for the development of grade 4 neutropenia, febrile
neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase
> 1.5 x ULN also had a higher rate of febrile neutropenia grade 4 but did
not have an increased incidence of toxic death. Bilirubin, SGOT or SGPT, and
alkaline phosphatase values should be obtained prior to each cycle of TAXOTERE
therapy and reviewed by the treating physician. TAXOTERE therapy should not
be given to patients with neutrophil counts of < 1500 cells/mm3.
In order to monitor the occurrence of neutropenia, which may be severe and
result in infection, frequent blood cell counts should be performed on all
patients receiving TAXOTERE. Severe hypersensitivity reactions characterized
by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely
fatal anaphylaxis, have been reported in patients who received the recommended
3-day dexamethasone premedication. Hypersensitivity reactions require immediate
discontinuation of the TAXOTERE infusion and administration of appropriate
therapy [see Warnings and Precautions].
TAXOTERE must not be given to patients who have a history of severe hypersensitivity
reactions to TAXOTERE or to other drugs formulated with polysorbate 80 [see
Contraindications].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of
a 3-day dexamethasone premedication regimen. It was characterized by one or
more of the following events: poorly tolerated peripheral edema, generalized
edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac
tamponade, or pronounced abdominal distention (due to ascites) [see Warnings
and Precautions].

DRUG DESCRIPTION



What are the possible side effects of docetaxel (Taxotere)?

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Taxotere »




Docetaxel is an antineoplastic agent belonging to the taxoid family. It is
prepared by semisynthesis beginning with a precursor extracted from the renewable
needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl
ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one
4-acetate 2-benzoate, trihydrate. Docetaxel has the following structural formula:







Docetaxel is a white to almost-white powder with an empirical formula of C43H53NO14•3H2O,
and a molecular weight of 861.9. It is highly lipophilic and practically insoluble
in water. TAXOTERE (docetaxel) Injection Concentrate is a clear yellow to brownish-yellow
viscous solution. TAXOTERE is sterile, non-pyrogenic, and is available in single-dose
vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous). Each
mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80.
TAXOTERE Injection Concentrate requires dilution prior to use. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.
Last reviewed on RxList: 10/18/2007




Taxotere Drug Description
TAXOTERE
(docetaxel) Injection Concentrate, Intravenous Infusion

WARNING
The incidence of treatment-related mortality associated with TAXOTERE therapy
is increased in patients with abnormal liver function, in patients receiving
higher doses, and in patients with non-small cell lung carcinoma and a history
of prior treatment with platinum-based chemotherapy who receive TAXOTERE as
a single agent at a dose of 100 mg/m2 [see Warnings and Precautions].
TAXOTERE should generally not be given to patients with bilirubin > upper
limit of normal (ULN), or to patients with SGOT and/or SGPT > 1.5 x ULN
concomitant with alkaline phosphatase > 2.5 x ULN. Patients with elevations
of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase
are at increased risk for the development of grade 4 neutropenia, febrile
neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase
> 1.5 x ULN also had a higher rate of febrile neutropenia grade 4 but did
not have an increased incidence of toxic death. Bilirubin, SGOT or SGPT, and
alkaline phosphatase values should be obtained prior to each cycle of TAXOTERE
therapy and reviewed by the treating physician. TAXOTERE therapy should not
be given to patients with neutrophil counts of < 1500 cells/mm3.
In order to monitor the occurrence of neutropenia, which may be severe and
result in infection, frequent blood cell counts should be performed on all
patients receiving TAXOTERE. Severe hypersensitivity reactions characterized
by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely
fatal anaphylaxis, have been reported in patients who received the recommended
3-day dexamethasone premedication. Hypersensitivity reactions require immediate
discontinuation of the TAXOTERE infusion and administration of appropriate
therapy [see Warnings and Precautions].
TAXOTERE must not be given to patients who have a history of severe hypersensitivity
reactions to TAXOTERE or to other drugs formulated with polysorbate 80 [see
Contraindications].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of
a 3-day dexamethasone premedication regimen. It was characterized by one or
more of the following events: poorly tolerated peripheral edema, generalized
edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac
tamponade, or pronounced abdominal distention (due to ascites) [see Warnings
and Precautions].

DRUG DESCRIPTION



What are the possible side effects of docetaxel (Taxotere)?

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Taxotere »




Docetaxel is an antineoplastic agent belonging to the taxoid family. It is
prepared by semisynthesis beginning with a precursor extracted from the renewable
needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl
ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one
4-acetate 2-benzoate, trihydrate. Docetaxel has the following structural formula:







Docetaxel is a white to almost-white powder with an empirical formula of C43H53NO14•3H2O,
and a molecular weight of 861.9. It is highly lipophilic and practically insoluble
in water. TAXOTERE (docetaxel) Injection Concentrate is a clear yellow to brownish-yellow
viscous solution. TAXOTERE is sterile, non-pyrogenic, and is available in single-dose
vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous). Each
mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80.
TAXOTERE Injection Concentrate requires dilution prior to use. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.
Last reviewed on RxList: 10/18/2007





Other reviews about Taxotere on web:

Docetaxel (trade name Taxotere) is a clinically well established anti-mitotic chemotherapy medication (that is, it interferes with cell division). Docetaxel - Wikipedia, the free encyclopedia


Learn about the prescription medication Taxotere (Docetaxel for Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Taxotere (Docetaxel for Injection) Drug Information: Uses, Side ...


Taxotere (docetaxel) treats breast cancer, lung cancer, prostate cancer and stomach cancer. Includes Taxotere side effects, interactions and indications. Taxotere Information from Drugs.com


Taxotere is the trade name for the generic chemotherapy drug Docetaxel. Taxotere is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug classified as a plant ... Taxotere, Docetaxel - Chemotherapy Drugs, Chemo Drug Side Effects


Information about Actonel, Allegra, Ambien, Apidra, Elitek, Eloxatin, Hyalgan, Ketek, Lovenox, Nasacort, Lantus, Plavix, Taxotere and Uroxatral sanofi-aventis products


Accurate, FDA approved Taxotere information for healthcare professionals and patients - brought to you by Drugs.com. Taxotere Official FDA information, side effects and uses.


Taxotere is a drug that is approved to treat breast cancer, prostate cancer, and other types of cancer. This eMedTV article offers a more in-depth look at Taxotere and its ... Taxotere


Taxotere is a chemotherapy drug used in treating cancer, especially advanced cases of breast cancer. It's trade name is docetaxel. Learn information of side effects of Taxotere ... Taxotere


Buy Taxotere Cancer Medication Online. Canadian Pharmacy. Vast selection of online medication for a range of medical conditions. Online Pharmacy. Buy Taxotere | Cancer Medication - Online Pharmacy


Definition of Taxotere – Our online dictionary has Taxotere information from A Dictionary of Nursing dictionary. Encyclopedia.com: English, psychology and medical dictionaries Taxotere – Dictionary definition of Taxotere | Encyclopedia.com ...





Featured Reviews

Reviews Renova 0.02%

Renova 0.02% Drug Description RENOVA® (tretinoin) Cream 0.02% FOR TOPICAL USE ON THE FACE. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. DRUG DESCRIPTION What are the possible side effects of tretinoin topical? Stop using...
Read More  |  Review This
Reviews Azithromycin

Zithromax Drug Description ZITHROMAX® (azithromycin)  Tablets and Oral Suspension To reduce the development of drug-resistant bacteria and maintain the effectiveness of Zithromax® (azithromycin) and other antibacterial drugs,...
Read More  |  Review This
Reviews Nucynta

Nucynta Drug Description NUCYNTA® (tapentadol) Tablets DRUG DESCRIPTION What are the possible side effects of tapentadol (Nucynta)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Malarone

Malarone Drug Description MALARONE® (atovaquone and proguanil hydrochloride) Tablets MALARONE® (atovaquone and proguanil hydrochloride) Pediatric Tablets DRUG DESCRIPTION What are the possible side effects of atovaquone...
Read More  |  Review This
Reviews Fentanyl Iontophoretic Transdermal System

Ionsys Drug Description IONSYS™ (fentanyl iontophoretic transdermal system) 40 mcg*/activation Patient-activated * Equals to 44.4 mcg fentanyl HCl IONSYS™ should only be used for the treatment of hospitalized...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....